Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG; Australian Mepolizumab Registry Investigators. Kritikos V, et al. Among authors: gillman a. J Allergy Clin Immunol Pract. 2023 Mar;11(3):885-895.e13. doi: 10.1016/j.jaip.2022.12.004. Epub 2022 Dec 23. J Allergy Clin Immunol Pract. 2023. PMID: 36572182
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
Gibson PG, Reddel H, McDonald VM, Marks G, Jenkins C, Gillman A, Upham J, Sutherland M, Rimmer J, Thien F, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Robinson P, Wright C, Yozghatlian V, Burgess S, Sivakumaran P, Jaffe A, Bowden J, Wark PA, Yan KY, Kritikos V, Peters M, Hew M, Aminazad A, Bint M, Guo M. Gibson PG, et al. Among authors: gillman a. Intern Med J. 2016 Sep;46(9):1054-62. doi: 10.1111/imj.13166. Intern Med J. 2016. PMID: 27350385
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.
Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, Reddel HK, Jenkins C, Marks GB, Thien F, Rimmer J, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Wright C, Bint M, Yozghatlian V, Burgess S, Sivakumaran P, Yan KY, Kritikos V, Peters M, Baraket M, Aminazad A, Robinson P, Jaffe A, Powell H, Upham JW, McDonald VM, Gibson PG. Hew M, et al. Among authors: gillman a. Clin Exp Allergy. 2016 Nov;46(11):1407-1415. doi: 10.1111/cea.12774. Epub 2016 Jul 22. Clin Exp Allergy. 2016. PMID: 27377155
The first case of methemoglobinemia associated with omalizumab.
Kronborg C, Pumar M, Gillman A. Kronborg C, et al. Among authors: gillman a. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1414-1415. doi: 10.1016/j.jaip.2017.11.037. Epub 2018 Jan 12. J Allergy Clin Immunol Pract. 2018. PMID: 29339124 No abstract available.
The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors.
Thien F, Beggs PJ, Csutoros D, Darvall J, Hew M, Davies JM, Bardin PG, Bannister T, Barnes S, Bellomo R, Byrne T, Casamento A, Conron M, Cross A, Crosswell A, Douglass JA, Durie M, Dyett J, Ebert E, Erbas B, French C, Gelbart B, Gillman A, Harun NS, Huete A, Irving L, Karalapillai D, Ku D, Lachapelle P, Langton D, Lee J, Looker C, MacIsaac C, McCaffrey J, McDonald CF, McGain F, Newbigin E, O'Hehir R, Pilcher D, Prasad S, Rangamuwa K, Ruane L, Sarode V, Silver JD, Southcott AM, Subramaniam A, Suphioglu C, Susanto NH, Sutherland MF, Taori G, Taylor P, Torre P, Vetro J, Wigmore G, Young AC, Guest C. Thien F, et al. Among authors: gillman a. Lancet Planet Health. 2018 Jun;2(6):e255-e263. doi: 10.1016/S2542-5196(18)30120-7. Lancet Planet Health. 2018. PMID: 29880157 Free article.
The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admission.
Hew M, Lee J, Susanto NH, Prasad S, Bardin PG, Barnes S, Ruane L, Southcott AM, Gillman A, Young A, Rangamuwa K, O'Hehir RE, McDonald C, Sutherland M, Conron M, Matthews S, Harun NS, Lachapelle P, Douglass JA, Irving L, Langton D, Mann J, Erbas B, Thien F. Hew M, et al. Among authors: gillman a. Allergy. 2019 Jan;74(1):122-130. doi: 10.1111/all.13609. Epub 2018 Oct 11. Allergy. 2019. PMID: 30243030
Mepolizumab effectiveness and identification of super-responders in severe asthma.
Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, Bardin P, Peters M, Reynolds PN, Upham JW, Baraket M, Bowler S, Bowden J, Chien J, Chung LP, Grainge C, Jenkins C, Katsoulotos GP, Lee J, McDonald VM, Reddel HK, Rimmer J, Wark PAB, Gibson PG. Harvey ES, et al. Among authors: gillman a. Eur Respir J. 2020 May 21;55(5):1902420. doi: 10.1183/13993003.02420-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32139455 Free article.
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.
Thomas D, Harvey ES, McDonald VM, Stevens S, Upham JW, Katelaris CH, Kritikos V, Gillman A, Harrington J, Hew M, Bardin P, Peters M, Reynolds PN, Langton D, Baraket M, Bowden JJ, Bowler S, Chien J, Chung LP, Farah CS, Grainge C, Jenkins C, Katsoulotos GP, Lee J, Radhakrishna N, Reddel HK, Rimmer J, Sivakumaran P, Wark PAB, Gibson PG. Thomas D, et al. Among authors: gillman a. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2715-2724.e5. doi: 10.1016/j.jaip.2021.01.028. Epub 2021 Feb 3. J Allergy Clin Immunol Pract. 2021. PMID: 33545399
221 results